Jennifer C Cather
Overview
Explore the profile of Jennifer C Cather including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paller A, Seyger M, Magarinos G, Pinter A, Cather J, Rodriguez-Capriles C, et al.
JAMA Dermatol
. 2022 Apr;
158(5):533-541.
PMID: 35416908
Importance: About 1% of children and adolescents worldwide are affected by plaque psoriasis. Objective: To evaluate the long-term efficacy and safety of ixekizumab for pediatric patients with moderate to severe...
2.
Yosipovitch G, Foley P, Ryan C, Cather J, Meeuwis K, Burge R, et al.
J Sex Med
. 2018 Nov;
15(11):1645-1652.
PMID: 30415816
Introduction: Genital psoriasis (GenPs) is common and distressing for patients, but is often not discussed with physicians, and no previous clinical trials have assessed the effects of biologics specifically on...
3.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather J, Weisman J, Pariser D, et al.
Lancet
. 2017 May;
389(10086):2287-2303.
PMID: 28478972
Background: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week...
4.
Crowley J, Thaci D, Joly P, Peris K, Papp K, Goncalves J, et al.
J Am Acad Dermatol
. 2017 Apr;
77(2):310-317.e1.
PMID: 28416342
Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective: Assess long-term safety of oral apremilast in psoriasis patients. Methods: Safety findings...
5.
Menter A, Cather J, Jarratt M, Meng X, Guana A, Nyirady J
Dermatol Ther (Heidelb)
. 2016 Sep;
6(4):639-647.
PMID: 27576559
Introduction: The impact of psoriasis varies with the body region affected. In addition, patients have different perceptions of disease improvement and treatment satisfaction based on the location of skin clearance...
6.
Cather J, Crowley J
Am J Clin Dermatol
. 2014 Nov;
15(6):467-78.
PMID: 25373522
Psoriasis is a chronic inflammatory skin disorder, which is associated with a significant negative impact on a patient's quality of life. Traditional therapies for psoriasis are often not able to...
7.
Cather J
Semin Cutan Med Surg
. 2014 Jul;
33(2 Suppl 2):S42-4.
PMID: 24979545
Psoriasis is a lifelong, chronic disease that affects all ages. For some, psoriasis begins in childhood, and education of both pediatric patients and their parents is essential to successful and...
8.
Furst D, Mandell B, Calabrese L, Cather J, Clauw D, Deodhar A, et al.
Semin Arthritis Rheum
. 2013 Dec;
43(3):416-9.
PMID: 24326035
Objectives: Update on rheumatic diseases and their intersection with dermatology. Results: This continuing medical education conference included more than 25 presentations and interactive sessions from leading experts in managing rheumatic...
9.
Papp K, Cather J, Rosoph L, Sofen H, Langley R, Matheson R, et al.
Lancet
. 2012 Jul;
380(9843):738-46.
PMID: 22748702
Background: Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment...
10.
Young M, Horn E, Cather J
Expert Rev Clin Immunol
. 2010 Dec;
7(1):9-13.
PMID: 21162644
The first biologic therapy for psoriasis was approved in 2003. Other approvals followed, including TNF-α inhibitors, and in addition to providing new treatment options that were greatly needed, these therapies...